Senate gets on its knees to pay their debts to the Big Pharma Pimps….

So essentially, the senate has said if you’re elderly and poor where you have to choose between medicine to live, or food to live, screw you. You should have contributed to my campain fund. This is really, really sad. Well, time to invest in companies that build prisons, they’ll start filling up with old people.

Senate Vote Blocks Imported Drugs | World Latest | Guardian Unlimited In a triumph for the pharmaceutical industry, the Senate on Monday killed a drive to allow consumers to buy prescription drugs from abroad at a significant savings over domestic prices. On a 49-40 vote, the Senate required the administration to certify the safety and effectiveness of imported drugs before they can be imported, a requirement that officials have said they cannot meet. “Well, once again the big drug companies have proved that they are the most powerful and best financed lobby in Washington,” said Sen. David Vitter, a Louisiana Republican.

3 thoughts on “Senate gets on its knees to pay their debts to the Big Pharma Pimps….

  1. DAMIT!!! If we can outsource IT jobs surely we can import foreign pills for the elderly. Why can’t the FDA create a certified list of trusted governments whose drug administrations have themselves certified drugs as the FDA does.
    Does a drug have to go through trials in every country? I’m sure the European Union has a drug certification process for EU members and if we tapped into that process US drug companies would have competition and the cost to certify drugs would go down, thus bringing down the cost of drugs.
    Big mess…

  2. It’s a sham HH. The FDA is under pressure by the current administration and certain congressional people who support big pharma. Remember, the Medicare bill was practically written by pharma companies.  And all those congressional reps who help in that previous bill have been rewarded with jobs at the companies now. Big thank you paying jobs. This issue of certifying drugs out of country is just a tactic by the administration to protect pharma companies’ revenue streams.

Comments are closed.